MX2021007003A - Método para tratar el cáncer. - Google Patents

Método para tratar el cáncer.

Info

Publication number
MX2021007003A
MX2021007003A MX2021007003A MX2021007003A MX2021007003A MX 2021007003 A MX2021007003 A MX 2021007003A MX 2021007003 A MX2021007003 A MX 2021007003A MX 2021007003 A MX2021007003 A MX 2021007003A MX 2021007003 A MX2021007003 A MX 2021007003A
Authority
MX
Mexico
Prior art keywords
cell
cancer
subject
ezh2
treating cancer
Prior art date
Application number
MX2021007003A
Other languages
English (en)
Inventor
Heike Keilhack
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of MX2021007003A publication Critical patent/MX2021007003A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un método para tratar o aliviar un síntoma de un trastorno, p. ej., una evasión inmunológica, disfunción inmunológica inducida por células cancerosas, respuesta inmunológica reducida, inflamación reducida, expresión disminuida de un complejo principal de histocompatibilidad (MHC), o cáncer, caracterizado por una actividad y/o expresión aberrante, regulada erróneamente o incrementada del potenciador del Zeste homólogo 2 (EZH2) en una célula o sujeto en necesidad del mismo, poniendo en contacto la célula o administrando al sujeto una cantidad terapéuticamente eficaz de un inhibidor de EZH2.
MX2021007003A 2014-10-16 2015-10-16 Método para tratar el cáncer. MX2021007003A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462064948P 2014-10-16 2014-10-16
US201462065590P 2014-10-17 2014-10-17
PCT/US2015/056022 WO2016061507A1 (en) 2014-10-16 2015-10-16 Method for treating cancer

Publications (1)

Publication Number Publication Date
MX2021007003A true MX2021007003A (es) 2022-08-09

Family

ID=55747431

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021007003A MX2021007003A (es) 2014-10-16 2015-10-16 Método para tratar el cáncer.
MX2017004969A MX2017004969A (es) 2014-10-16 2015-10-16 Metodo para tratar el cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017004969A MX2017004969A (es) 2014-10-16 2015-10-16 Metodo para tratar el cancer.

Country Status (14)

Country Link
US (4) US9889138B2 (es)
EP (1) EP3206688A4 (es)
JP (4) JP2017532338A (es)
KR (1) KR102397720B1 (es)
CN (2) CN112168967A (es)
AU (3) AU2015331729A1 (es)
BR (1) BR112017007738B1 (es)
CA (1) CA2963149A1 (es)
EA (1) EA201790845A1 (es)
IL (4) IL310279A (es)
MX (2) MX2021007003A (es)
NZ (1) NZ730365A (es)
SG (2) SG10201903356XA (es)
WO (1) WO2016061507A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6351182B2 (ja) * 2012-10-15 2018-07-04 エピザイム，インコーポレイティド ガンの治療方法
MX2021007003A (es) 2014-10-16 2022-08-09 Epizyme Inc Método para tratar el cáncer.
HUE062159T2 (hu) 2014-11-17 2023-10-28 Epizyme Inc Módszer a rák kezelésére N-((4,6-dimetil-2-oxo-l,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H -pirán-4-il)amino)-4-metil-4'-(morfolinmetil)-[1,1'-bifenil]-3-karboxamiddal
CA2983265A1 (en) 2015-04-20 2016-10-27 Health Research, Inc. Combination therapy for treating cancer
EP3307713A4 (en) 2015-06-10 2019-01-23 Epizyme, Inc. EZH2 INHIBITOR FOR THE TREATMENT OF LYMPHOMA
JP2018525414A (ja) 2015-08-24 2018-09-06 エピザイム，インコーポレイティド 癌を処置するための方法
US11951108B2 (en) 2016-01-29 2024-04-09 Epizyme, Inc. Combination therapy for treating cancer
EP3464643A4 (en) * 2016-06-01 2020-04-01 Epizyme Inc USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER
US11147819B2 (en) 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
WO2018076060A1 (en) 2016-10-26 2018-05-03 Genea Ip Holdings Pty Ltd Improved generation of muscle lineage cells and therapeutic uses thereof
KR101913693B1 (ko) * 2016-12-14 2018-10-31 사회복지법인 삼성생명공익재단 SS18-SSX 융합 유전자 특이적 siRNA 및 이를 포함하는 암 예방 또는 치료용 약학적 조성물
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
US11602529B2 (en) 2017-06-02 2023-03-14 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
WO2019050924A1 (en) 2017-09-05 2019-03-14 Epizyme, Inc. POLY THERAPY FOR THE TREATMENT OF CANCER
CN112533581A (zh) * 2018-06-07 2021-03-19 密歇根大学董事会 Prc1抑制剂及用其进行治疗的方法
WO2023159124A2 (en) * 2022-02-17 2023-08-24 Memorial Sloan-Kettering Cancer Center Methods for overcoming tazemetostat-resistance in cancer patients

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1036915A (en) 1911-05-25 1912-08-27 Joseph Schindler Utilizing exhaust-steam.
CA3151350A1 (en) * 2005-05-09 2006-11-16 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US8895245B2 (en) 2010-09-10 2014-11-25 Epizyme, Inc. Inhibitors of human EZH2 and methods of use thereof
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
KR102453519B1 (ko) * 2012-03-12 2022-10-11 에피자임, 인코포레이티드 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
SG10201608579UA (en) * 2012-04-13 2016-12-29 Epizyme Inc Combination therapy for treating cancer
HUE031976T2 (en) 2012-04-13 2017-08-28 Epizyme Inc Human form of histone methyl transferase inhibitor EZH2
CN110041250A (zh) 2012-10-15 2019-07-23 Epizyme股份有限公司 经取代的苯化合物
JP6351182B2 (ja) * 2012-10-15 2018-07-04 エピザイム，インコーポレイティド ガンの治療方法
WO2014100080A1 (en) * 2012-12-19 2014-06-26 Glaxosmithkline Llc Combination
US20150344427A1 (en) 2012-12-21 2015-12-03 Epizyme, Inc. 1,4-pyridone compounds
CA2894222A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
WO2014172044A1 (en) 2013-03-15 2014-10-23 Epizyme, Inc. Substituted benzene compounds
WO2014144747A1 (en) 2013-03-15 2014-09-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US9624205B2 (en) 2013-07-19 2017-04-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2015010049A1 (en) 2013-07-19 2015-01-22 Epizyme, Inc. Substituted benzene compounds
US10040782B2 (en) 2013-10-16 2018-08-07 Epizyme, Inc. Hydrochloride salt form for EZH2 inhibition
US20160228447A1 (en) 2013-10-18 2016-08-11 Epizyme, Inc. Method of treating cancer
IL282741B2 (en) * 2013-12-06 2024-01-01 Epizyme Inc Tazematostat in combination with an acceptable treatment factor for use in the treatment of cancer
IL285201B2 (en) * 2014-06-17 2024-05-01 Epizyme Inc EZH2 inhibitors for the treatment of lymphoma
US20170217941A1 (en) 2014-06-25 2017-08-03 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
MX2021007003A (es) * 2014-10-16 2022-08-09 Epizyme Inc Método para tratar el cáncer.

Also Published As

Publication number Publication date
US10369155B2 (en) 2019-08-06
AU2021200995B2 (en) 2022-06-02
US10946024B2 (en) 2021-03-16
AU2021200995A1 (en) 2021-03-11
IL289947B1 (en) 2024-02-01
US20180133224A1 (en) 2018-05-17
US20210267990A1 (en) 2021-09-02
CN106794177A (zh) 2017-05-31
IL289947B2 (en) 2024-06-01
MX2017004969A (es) 2017-07-19
WO2016061507A1 (en) 2016-04-21
IL310279A (en) 2024-03-01
JP2017532338A (ja) 2017-11-02
IL276545A (en) 2020-09-30
EA201790845A1 (ru) 2017-08-31
EP3206688A4 (en) 2018-06-13
KR102397720B1 (ko) 2022-05-13
IL289947A (en) 2022-03-01
CA2963149A1 (en) 2016-04-21
IL251411B (en) 2020-08-31
BR112017007738B1 (pt) 2023-04-11
US20200009152A1 (en) 2020-01-09
KR20170070140A (ko) 2017-06-21
EP3206688A1 (en) 2017-08-23
AU2022221580A1 (en) 2022-09-22
SG11201702488YA (en) 2017-04-27
JP2020097615A (ja) 2020-06-25
JP2023109922A (ja) 2023-08-08
BR112017007738A2 (pt) 2018-01-30
US9889138B2 (en) 2018-02-13
NZ730365A (en) 2024-03-22
CN112168967A (zh) 2021-01-05
SG10201903356XA (en) 2019-05-30
AU2015331729A1 (en) 2017-04-13
US20160346293A1 (en) 2016-12-01
IL251411A0 (en) 2017-05-29
JP2021105022A (ja) 2021-07-26
IL276545B (en) 2022-02-01

Similar Documents

Publication Publication Date Title
NZ730365A (en) Method for treating cancer
MX2022001757A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte programada 1 (pd-l1) para el tratamiento de cancer.
MX2018014435A (es) Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer.
MX2017001154A (es) Metodos y combinaciones terapeuticas para tratar tumores.
NZ748192A (en) Methods of treating skin cancer by administering a pd-1 inhibitor
MX2019005465A (es) Metodo de tratamiento de un tumor inmunoterapeutico.
MX2018012132A (es) Reduccion de carga tumoral mediante administracion de antagonistas de ccr1 en combinacion con inhibidores de muerte-1 programada (pd-1) o inhibidores de ligando-1 de muerte-1 programada (pd-l1).
SG10201811841UA (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MX2018004132A (es) Método de tratamiento de meduloblastoma con un inhibidor de ezh2.
MX2022013390A (es) Metodo de tratamiento de tumor rabdoide maligno del ovario (mrto)/cancer microcitico del ovario del tipo hipercalcemico (sccoht) con un inhibidor de ezh2.
MY177740A (en) Treatment of cataplexy
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
MX2017001686A (es) Anticuerpos anti-ceramida.
NZ722600A (en) Methods of treating mild brain injury
PH12016502244A1 (en) Hsp70 modulators and methods for making and using the same
PH12016500903A1 (en) Novel methods for treating neurodegenerative diseases
MX2019006694A (es) Oxabicicloheptanos para la modulacion de la respuesta inmunitaria.
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
MX2020011766A (es) Metodos de administracion de tratamiento antifibrotico.
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
WO2015134603A3 (en) Methods for treating cancer
NZ728612A (en) Treatment of androgen deprivation therapy associated symptoms
MX2019014291A (es) Metodo de tratamiento.
NZ725067A (en) Anti-tumor agent containing anti-tumor platinum complex, and anti-tumor effect enhancer